Delivering on the promise of science in life sciences
To accelerate progress, the industry will need to focus on strategic imperatives and fundamentally change the drug development paradigm
Add BT as a preferred source
Kavita Rekhraj
CHANGE will persist throughout 2022 and beyond for the life sciences sector in Southeast Asia. Armed with new sources of insights and real-world evidence, companies will be solving problems for diseases that were once thought intractable. New processes adopted during the pandemic to expedite Covid-19 vaccines and therapeutic products will also be applied to accelerate the development of other drugs and treatments.
In the year ahead, the greatest challenge confronting life sciences leaders will be to ensure that they accelerate the valuable progress made – and not revert to old ways. To address this, they will need to focus on three strategic imperatives to capitalise on their digital progress, and fundamentally change the drug development paradigm:
TRENDING NOW
Father-and-son duo Raj Kumar and Kishin in exclusive due diligence to buy Scotts Square
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Koh Brothers Eco Engineering faces up to S$57.6 million in potential legal liabilities
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
